The crowd of novel PD-1/L1 inhibitors seeking FDA approval shrank by one on 22 October 2021, when Agenus Inc. announced the withdrawal of its biologics license application for accelerated approval of balstilimab for recurrent or metastatic cervical cancer patients with disease progression on or after chemotherapy.
The precipitating factor was the FDA’s 13 October conversion from accelerated to full approval of a chemotherapy-experienced PD-L1-positive cervical cancer...






